Form 4: Tango Therapeutics CFO Matthew Gall Receives Equity Grant

Tango Therapeutics CFO Matthew Gall was granted 40,000 restricted stock units and 240,000 stock options as part of a compensation package.

Summary

• Matthew Gall, Chief Financial Officer of Tango Therapeutics, Inc., received an equity grant on May 1, 2026.
• The grant includes 40,000 restricted stock units (RSUs) and 240,000 stock options.
• The RSUs vest over a three-year period ending in May 2029.
• The stock options have an exercise price of $20.98 and vest over a four-year period starting in April 2027.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding executive compensation, which is expected behavior for a publicly traded company.

Positives

• Equity-based compensation aligns the interests of the CFO with long-term shareholder value.
• Multi-year vesting schedules for both RSUs and options encourage executive retention.

Negatives

• The issuance of new equity grants results in potential dilution for existing shareholders.

Risks

• Vesting is contingent upon the reporting person's continuous service with the issuer.
• Stock options are subject to market volatility and may remain underwater if the share price does not exceed the $20.98 exercise price.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on executive compensation changes.

Industry Context

StockSavvy.ai notes that equity-based compensation is standard practice in the biotechnology sector to attract and retain executive talent, particularly for companies in the clinical development stage.

Comparison to Industry Standards

• The use of multi-year vesting schedules (3-4 years) is consistent with standard corporate governance practices for executive compensation in the U.S. biotech industry.
• Granting a mix of RSUs and stock options is a common strategy to balance immediate equity ownership with performance-based incentives.

Stakeholder Impact

• Shareholders may experience minor dilution due to the issuance of new equity.

Next Steps

• Vesting of RSUs beginning May 2027.
• Vesting of stock options beginning April 2027.

Key Dates

Keywords

Tango Therapeutics, TNGX, Form 4, Insider Trading, Equity Compensation, CFO